Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib

BACKGROUND: Sunitinib prolonged progression-free survival (PFS) versus placebo in patients with metastatic pancreatic neuroendocrine tumors (panNETs) in a phase III trial. The efficacy and safety of sunitinib in patients with panNETs were confirmed in an open-label phase IV trial. OBJECTIVE: To asse...

Descripción completa

Detalles Bibliográficos
Autores principales: Fazio, Nicola, Kulke, Matthew, Rosbrook, Brad, Fernandez, Kathrine, Raymond, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810649/
https://www.ncbi.nlm.nih.gov/pubmed/33411058
http://dx.doi.org/10.1007/s11523-020-00784-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810649/
https://www.ncbi.nlm.nih.gov/pubmed/33411058
http://dx.doi.org/10.1007/s11523-020-00784-0

Ejemplares similares